KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52-week, multicentre, randomized, placebo-controlled, phase III clinical trial.

Eun-Gyoung Hong, Kyung-Wan Min, SungWan Chun, Choon Hee Chung, Seungjoon Oh, Chang Beom Lee, Dong-Jun Kim, Hye Soon Kim, Ji Oh Mok, Tae Seo Sohn, Jeong Hyun Park, Sung Hee Choi, Sungrae Kim, Sang Soo Kim, Kyu Yeon Hur, Chong Hwa Kim, Young Min Cho, Byung-Joon Kim, Kun-Ho Yoon

Diabetes Obes Metab 27(10) 5727-5736

PMID40726438
PMCIDPMC12409244
DOI10.1111/dom.16625
发表日期2025-07-29
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other。
摘要

摘要

AIMS: To evaluate the efficacy and safety of adding lobeglitazone to a triple therapy regimen in Korean patients with type 2 diabetes whose blood glucose levels were inadequately controlled despite dual therapy with metformin and sitagliptin. MATERIALS AND METHODS: This randomised, double-blind, placebo-controlled, phase 3 study involved 231 Korean patients with type 2 diabetes whose HbA1c levels ranged from 7.0% to 10.0% despite treatment with metformin (≥1000 mg/day) and sitagliptin (100 mg/day). Participants received lobeglitazone (0.5 mg/day) or placebo for 24 weeks, followed by a 28-week open-label phase in which all patients received lobeglitazone. The primary endpoint was the change in glycated haemoglobin (HbA1c) at 24 weeks; secondary endpoints included changes in fasting plasma glucose (FPG), homeostatic model assessment for insulin resistance (HOMA-IR), HOMA for β-cell function (HOMA-β), quantitative insulin-sensitivity check index (QUICKI) and lipid profile. Safety assessments were also conducted. RESULTS: At week 24, lobeglitazone treatment demonstrated a significantly greater reduction in HbA1c compared with placebo (-1.00% ± 0.09% vs. 0.02% ± 0.09%), with a between-group difference in the adjusted mean change [-1.03%; p < 0.0001]. Additionally, lobeglitazone significantly reduced FPG compared with placebo at week 24 and improved HOMA-IR, HOMA-β and QUICKI. Lipid parameters were also improved by lobeglitazone administration. Adverse events were similar in both treatment arms. CONCLUSIONS: The addition of lobeglitazone in patients with type 2 diabetes inadequately controlled with metformin and sitagliptin is a beneficial therapeutic option, not only providing effective glycaemic control but also improving insulin function such as sensitivity and enhancing certain lipid parameters.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Patient disposition. a Safety set includes all randomised patients administered the investigational product (placebo or lobeglitazone) at least once. b mFAS (modified full analysis set) is defined as the group of patients in the safety set who had HbA1c levels measured at baseline and at least once afterward, without exceeding the visit window. c mPPS (modified per‐protocol set) includes the population from the mFAS who had no major protocol deviations with medication adherence of 80%–120%. However, patients who were deemed likely to seriously impact the efficacy evaluation (e.g., continuous administration of rescue medication) or violated the visit window at the primary assessment timepoint were excluded from this analysis set.
非 KM Figure
FIGURE 2FIGURE 2 (A) Adjusted mean change from baseline in HbA1c levels over 52 weeks, and (B) proportion of patients achieving HbA1c < 7.0% or < 6.5% at weeks 24 and 52; adjusted mean changes from baseline over 52 weeks in: (C) fasting plasma glucose (FPG) levels, (D) homeostasis model assessment of insulin resistance (HOMA‐IR), (E) homeostasis model assessment of β‐cell function (HOMA‐β) and (F) quantitative insulin sensitivity check index (QUICKI). Error bars represent standard errors (SEs) of the mean. Significant change from baseline: a p < 0.05, b p < 0.0001; significant difference between groups: * p < 0.05, ** p < 0.0001.
非 KM Figure
FIGURE 3FIGURE 3 Adjusted mean changes from baseline over 52 weeks in: (A) low‐density lipoprotein cholesterol (LDL‐C), (B) high‐density lipoprotein cholesterol (HDL‐C), small dense LDL‐C and (C, D) free fatty acid (FFA) levels. Error bars represent standard errors (SEs) of the mean. Significant change from baseline: a p < 0.05, b p < 0.0001; significant difference between groups: * p < 0.05, ** p < 0.0001.
非 KM Figure